INVESTMENTS THAT MATTER

Agent Capital is a healthcare venture capital firm focused on investing in novel, differentiated therapeutics and treatments that address unmet patient needs.

Across all stages of development, we align ourselves with scientists, entrepreneurs and other investors to develop the next generation of healthcare innovations that will have a positive impact on patients’ lives.

OUR PROVEN STRATEGY

At Agent Capital, we proactively guide biotech companies to milestones and exits.

With a balanced investment approach and a deep understanding of biopharma’s pipeline pressures, we are committed to making investments that move healthcare forward – no matter the stage or investment type.

TYPICALLY, OUR KEY INVESTMENT AREAS OF FOCUS INCLUDE:

Rare Diseases
Oncology
Neurology
Immunology
Learn More

Featured Portfolio Company

Dice Therapeutics

Freenome

Metagenomi

Pliant Therapeutics

ViTToria Biotherapeutics

Dragonfly Therapeutics

Carisma Therapeutics

Skyhawk Therapeutics

Flare Therapeutics

ImCheck Therapeutics

Orchard Therapeutics

Entrada Therapeutics

Zenas Biopharma

Star Therapeutics

Pyxis Oncology

Precision Biosciences

Palvella Therapeutics

View Full Portfolio

Featured News

Press Release | July 10, 2024

Skyhawk Therapeutics Announces Positive Topline Results of SKY-0515 as a Treatment for Huntington’s Disease, Reaching 72% Huntingtin mRNA Reduction

Read More

Press Release | July 9, 2024

Interius BioTherapeutics Receives HREC Approval and CTN Clearance from the TGA to Commence a Phase 1 Clinical Trial for Its First-in-Class In Vivo CAR Therapeutic for B Cell Malignancies

Read More

Press Release | June 27, 2024

« Back Carisma Therapeutics Announces Nomination of First In Vivo CAR-M Development Candidate for Hepatocellular Carcinoma Under Collaboration with Moderna

Read More

View All